 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | NC410 / NextCure
Phase classification, Checkpoint inhibition, Metastases: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 28, 2024
P1/2, N=131, Recruiting, Sponsor: NextCure, Inc.
Phase classification: P1b/2 --> P1/2
- | NC410 / NextCure
Preclinical, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. (Pubmed Central) - Jan 18, 2024
However, combined targeting of LAIR-1 and PD-L1 results in increased tumour control. Thus, additional targeting of the LAIR-1:collagen pathway with NC410 is a promising approach to treating tumours where conventional immunotherapy is ineffective.
- | NC410 / NextCure
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 14, 2023
P1/2, N=46, Terminated, Sponsor: NextCure, Inc.
Thus, additional targeting of the LAIR-1:collagen pathway with NC410 is a promising approach to treating tumours where conventional immunotherapy is ineffective. N=128 --> 46 | Trial completion date: Dec 2023 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors.
- || NC410 / NextCure
Enrollment closed, Metastases: A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 10, 2023
P1/2, N=128, Active, not recruiting, Sponsor: NextCure, Inc.
N=128 --> 46 | Trial completion date: Dec 2023 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors. Recruiting --> Active, not recruiting
- NC410 / NextCure, Keytruda (pembrolizumab) / Merck (MSD)
A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1056;
Objective response rate (ORR) based on RECIST v1.1 will be the primary endpoint, while duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), and overall survival will be evaluated as secondary endpoints. Several biomarker effects of NC410 in combination with pembrolizumab in peripheral blood and tumor tissue will be assessed.
- | NC410 / NextCure
Journal: Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. (Pubmed Central) - Dec 1, 2021
Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1 immune cells are localized. Our findings show that NC410 might be a novel strategy for cancer immunotherapy for immune-excluded tumors.
- NC410 / NextCure
NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_440;
P1/2
Further evaluation will be done with increasing doses to confirm these initial findings. Trial Registration NCT04408599
- || NC410 / NextCure
Trial completion date, Trial primary completion date, Metastases: A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=128, Recruiting, Sponsor: NextCure, Inc.
Trial Registration NCT04408599 Trial completion date: Jan 2023 --> Dec 2023 | Trial primary completion date: Jan 2023 --> Dec 2023
- ||| NC410 / NextCure
Preclinical: $NXTC NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410 https://t.co/oyo9Esx4Fj (Twitter) - Jun 21, 2021
- NC410 / NextCure
[VIRTUAL] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2716;
P1/2
Ongoing exploratory analyses include the assessment of predictive biomarkers associated with treatment benefit, and pharmacodynamic markers associated with study drug activity . Phase 2 is going to enroll ovarian, colorectal, NSCLC, H&N, and gastric carcinomas and other tumors depending on biomarker data available from the Phase 1 part of the study.
- ||| NC410 / NextCure
Enrollment open, Metastases: A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 11, 2020
P1/2, N=128, Recruiting, Sponsor: NextCure, Inc.
Phase 2 is going to enroll ovarian, colorectal, NSCLC, H&N, and gastric carcinomas and other tumors depending on biomarker data available from the Phase 1 part of the study. Not yet recruiting --> Recruiting
- |||| NC410 / NextCure
New P1/2 trial, Metastases: A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 28, 2020
P1/2, N=128, Not yet recruiting, Sponsor: NextCure, Inc.